Search results for "Umbilical"

showing 10 items of 331 documents

MicroRNA-148b-3p and MicroRNA-25-3p Are Overexpressed in Fetuses with Late-Onset Fetal Growth Restriction

2019

<b><i>Objective:</i></b> It was the aim of this study to describe a micro­RNA (miRNA) profile characteristic of late-onset fetal growth restriction (FGR) and to investigate the pathways involved in their biochemical action. <b><i>Methods:</i></b> In this prospective study, 25 fetuses (16 normal and 9 with FGR [estimated fetal weight <10th centile plus cerebroplacental ratio <0.6765 multiples of the median]) were evaluated with Doppler ultrasound after 36 weeks. Afterwards, for every fetus, plasma from umbilical vein blood was collected at birth, miRNA was extracted, and full miRNA sequencing was performed. Subsequently, compa…

MaleEmbryologyLate onsetUltrasonography PrenatalUmbilical veinAndrologyFetusDownregulation and upregulationPregnancymicroRNAFetal growthHumansMedicineRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyFetusFetal Growth Retardationbusiness.industryHigh-Throughput Nucleotide SequencingObstetrics and GynecologyUltrasonography DopplerGeneral MedicineFetal BloodPathophysiologyMicroRNAsCase-Control StudiesPediatrics Perinatology and Child HealthFemalebusinessFetal Diagnosis and Therapy
researchProduct

Spectrum of congenital anomalies in pregnancies with pregestational diabetes

2012

BACKGROUND Maternal pregestational diabetes is a well-known risk factor for congenital anomalies. This study analyses the spectrum of congenital anomalies associated with maternal diabetes using data from a large European database for the population-based surveillance of congenital anomalies. METHODS: Data from 18 population-based EUROCAT registries of congenital anomalies in 1990-2005. All malformed cases occurring to mothers with pregestational diabetes (diabetes cases) were compared to all malformed cases in the same registry areas to mothers without diabetes (non-diabetes cases). RESULTS: There were 669 diabetes cases and 92,976 non diabetes cases. Odds ratios in diabetes pregnancies re…

MaleEmbryologyPediatricsPregestational DiabetesPregnancy in DiabeticsMELLITUSPregnancyRisk FactorsNeural Tube DefectsRegistriesLivebirthsRISKeducation.field_of_studyOUTCOMESlivebirthsWOMENEarGeneral MedicineASSOCIATIONCongenital AnomaliesEuropeAnotiaPopulation SurveillanceFemaleNEURAL-TUBE DEFECTSLive BirthHernia UmbilicalAdultHeart Defects Congenitalmedicine.medical_specialtyPopulationPopulation Basedpopulation basedCongenital AbnormalitiesYoung AdultDiabetes mellitusAnencephalyBIRTH-DEFECTSmedicineDiabetes MellitusHumansMALFORMATIONSRisk factoreducationTYPE-1Congenital MicrotiaOmphaloceleSpina bifidabusiness.industrycongenital anomaliesInfant NewbornOdds ratioNATIONWIDEmedicine.diseaseEstados de Saúde e de Doençapregestational diabetesPregnancy ComplicationsPediatrics Perinatology and Child HealthbusinessDevelopmental BiologyBirth Defects Research. Part A: Clinical and Molecular Teratology
researchProduct

Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease

2016

We report the outcome of 30 consecutive patients with Hodgkin disease (HD) who underwent single-unit UCBT. Most (90%) patients had failed previous autologous hematopoietic stem cell transplantation. The conditioning regimens were based on combinations of thiotepa, busulfan, cyclophosphamide or fludarabine, and antithymocyte globulin. The cumulative incidence (CI) of myeloid engraftment was 90% [95% confidence interval (C.I.), 74-98%] with a median of 18 d (range, 10-48). CI of acute graft-versus-host disease (GvHD) grades II-IV was 30% (95% C.I., 17-44%), while the incidence of chronic GVHD was 42% (95% C.I., 23-77%). The non-relapse mortality (NRM) at 100 d and 4 yr was 30% (95% C.I., 13-4…

MaleHerpesvirus 4 HumanTransplantation Conditioningmedicine.medical_treatmentGraft vs Host DiseaseHematopoietic stem cell transplantationGastroenterology0302 clinical medicineRecurrencehemic and lymphatic diseasesCumulative incidenceHodgkin's lymphomaIncidence (epidemiology)Graft Survivalumbilical cord blood transplantationHematologyGeneral MedicineMiddle AgedHodgkin DiseaseFludarabine030220 oncology & carcinogenesisAcute DiseaseFemaleCord Blood Stem Cell TransplantationVidarabinemedicine.drugAdultmedicine.medical_specialtyCyclophosphamideThioTEPA03 medical and health sciencesInternal medicinemedicineHumansInfectious MononucleosisBusulfanCyclophosphamideAntilymphocyte Serumbusiness.industryMyeloablative AgonistsHodgkin's lymphomamedicine.diseaseSurvival AnalysisSurgeryEBV post-transplant lymphoproliferative diseaseChronic DiseaseEBV post-transplant lymphoproliferative disease; Hodgkin's disease; Hodgkin's lymphoma; umbilical cord blood transplantationHodgkin's diseasebusinessSettore MED/15 - Malattie del SangueThiotepaBusulfan030215 immunologyEuropean Journal of Haematology
researchProduct

Dense Bodies of a gH/gL/UL128/UL130/UL131 Pentamer-Repaired Towne Strain of Human Cytomegalovirus Induce an Enhanced Neutralizing Antibody Response

2019

The development of a vaccine against human cytomegalovirus infection (HCMV) is a high-priority medical goal. The viral pentameric protein complex consisting of glycoprotein H (gH)/gL/UL128-131A (PC) is considered to be an important vaccine component. Its relevance to the induction of a protective antibody response is, however, still a matter of debate. We addressed this issue by using subviral dense bodies (DBs) of HCMV. DBs are exceptionally immunogenic. Laboratory HCMV strain DBs harbor important neutralizing antibody targets, like the glycoproteins B, H, L, M, and N, but they are devoid of the PC. To be able to directly compare the impact of the PC on the levels of neutralizing antibody …

MaleHuman cytomegalovirusForeskinImmunologyCongenital cytomegalovirus infectionCytomegalovirusMutagenesis (molecular biology technique)MicrobiologyVirusCytomegalovirus VaccinesMiceViral Envelope ProteinsAntigenVirologyVaccines and Antiviral AgentsHuman Umbilical Vein Endothelial CellsmedicineAnimalsHumansNeutralizing antibodyCells Culturedchemistry.chemical_classificationMembrane GlycoproteinsbiologyImmunogenicitymedicine.diseaseAntibodies NeutralizingVirologychemistryMultiprotein ComplexesInsect ScienceCytomegalovirus Infectionsbiology.proteinRabbitsGlycoproteinJournal of Virology
researchProduct

Antiatherosclerotic Effects of Small-Molecular-Weight Compounds Enhancing Endothelial Nitric-Oxide Synthase (eNOS) Expression and Preventing eNOS Unc…

2008

Many cardiovascular diseases are associated with reduced levels of bioactive nitric oxide (NO) and an uncoupling of oxygen reduction from NO synthesis in endothelial NO synthase (eNOS uncoupling). In human endothelial EA.hy 926 cells, two small-molecular-weight compounds with related structures, 4-fluoro-N-indan-2-yl-benzamide (CAS no. 291756-32-6; empirical formula C16H14FNO; AVE9488) and 2,2-difluoro-benzo[1,3]dioxole-5-carboxylic acid indan-2-ylamide (CAS no. 450348-85-3; empirical formula C17H13F2NO3; AVE3085), enhanced eNOS promoter activity in a concentration-dependent manner; with the responsible cis-element localized within the proximal 263 base pairs of the promoter region. RNA int…

MaleNeointimamedicine.medical_specialtyNitric Oxide Synthase Type IIINitric Oxide Synthase Type IINitric OxideProtective AgentsUmbilical veinCell LineNitric oxideMicechemistry.chemical_compoundApolipoproteins EEnosInternal medicinemedicineAnimalsHumansBenzodioxolesRNA MessengerAortaMice KnockoutPharmacologychemistry.chemical_classificationSp1 transcription factorReactive oxygen speciesGene knockdownbiologyEndothelial CellsAtherosclerosisbiology.organism_classificationVasoprotectiveMice Inbred C57BLMolecular WeightEndocrinologychemistryBenzamidesIndansMolecular MedicineJournal of Pharmacology and Experimental Therapeutics
researchProduct

Flavonoids from Artichoke (Cynara scolymus L.) Up-Regulate Endothelial-Type Nitric-Oxide Synthase Gene Expression in Human Endothelial Cells

2004

Nitric oxide (NO) produced by endothelial nitric-oxide synthase (eNOS) represents an antithrombotic and anti-atherosclerotic principle in the vasculature. Hence, an enhanced expression of eNOS in response to pharmacological interventions could provide protection against cardiovascular diseases. In EA.hy 926 cells, a cell line derived from human umbilical vein endothelial cells (HUVECs), an artichoke leaf extract (ALE) increased the activity of the human eNOS promoter (determined by luciferase reporter gene assay). An organic subfraction from ALE was more potent in this respect than the crude extract, whereas an aqueous subfraction of ALE was without effect. ALE and the organic subfraction t…

MaleNitric Oxide Synthase Type IIIRNA StabilityQuinic AcidGene ExpressionCynarosideBiologyUmbilical veinNitric oxideRats Sprague-Dawleychemistry.chemical_compoundEnosCynara scolymusGene expressionAnimalsHumansRNA MessengerPromoter Regions GeneticAortaCells CulturedFlavonoidsPharmacologybiology.organism_classificationMolecular biologyRatsUp-RegulationVasomotor SystemNitric oxide synthasechemistryBiochemistryCell culturebiology.proteinMolecular MedicineEndothelium VascularNitric Oxide SynthaseLuteolinJournal of Pharmacology and Experimental Therapeutics
researchProduct

Arterial and Venous Endothelia Display Differential Functional Fractalkine (CX 3 CL1) Expression by Angiotensin-II

2012

Objective— Angiotensin-II (Ang-II) promotes the interaction of mononuclear cells with arterioles and neutrophils with postcapillary venules. To investigate the mechanisms underlying this dissimilar response, the involvement of fractalkine (CX 3 CL1) was explored. Methods and Results— Enhanced CX 3 CL1 expression was detected in both cremasteric arterioles and postcapillary venules 24 hours after Ang-II intrascrotal injection. Arteriolar leukocyte adhesion was the unique parameter significantly reduced (83%) in animals lacking CX 3 CL1 receptor (CX 3 CR1). Human umbilical arterial and venous endothelial cell stimulation with 1 μmol/L Ang-II increased CX 3 CL1 expression, yet neutralization …

MalePathologyTime Factorsp38 Mitogen-Activated Protein KinasesMiceVenulesLeukocytesEndothelial dysfunctionExtracellular Signal-Regulated MAP KinasesReceptorCells CulturedMice KnockoutMembrane GlycoproteinsAngiotensin IINF-kappa BArteriesEndothelial stem cellArteriolesNADPH Oxidase 5NADPH Oxidase 4NADPH Oxidase 2FemaleRNA InterferenceReceptors ChemokineTumor necrosis factor alphaCardiology and Cardiovascular MedicineSignal Transductionmedicine.medical_specialtyCX3C Chemokine Receptor 1BiologyTransfectionPeripheral blood mononuclear cellLosartanVeinsInterferon-gammaApolipoproteins EDownregulation and upregulationInternal medicineCell AdhesionHuman Umbilical Vein Endothelial CellsmedicineAnimalsHumansLeukocyte RollingCX3CL1Chemokine CX3CL1Tumor Necrosis Factor-alphaEndothelial CellsMembrane ProteinsNADPH OxidasesAtherosclerosismedicine.diseaseAngiotensin IIMice Inbred C57BLDisease Models AnimalEndocrinologyAngiotensin II Type 1 Receptor BlockersArteriosclerosis, Thrombosis, and Vascular Biology
researchProduct

IgA antiendomysial antibodies on the umbilical cord in diagnosing celiac disease. Sensitivity, specificity, and comparative evaluation with the tradi…

1996

The possibility of assaying antiendomysial antibodies (EmA) on the human umbilical cord instead of monkey esophagus has recently been suggested. We therefore evaluated in patients with celiac disease (CD) the sensitivity and specificity of EmA and of antigliadin antibodies (AGA) for both umbilical cord and monkey esophagus.We studied 36 patients with CD and atrophy of the intestinal mucosa (median age, 1.4 years), 14 patients with CD on gluten-free diet for 8-12 months (median age, 3.0 years), 36 controls without gastrointestinal disease (median age, 4.0 years), and 72 patients with cow's milk protein enteropathy (CMPE) (median age, 1.2 years). AGA and EmA on monkey esophagus were assayed w…

MalePathologymedicine.medical_specialtyAdolescentEnzyme-Linked Immunosorbent AssaySensitivity and SpecificityUmbilical cordGliadinCoeliac diseaseUmbilical CordEsophagusAtrophyIntestinal mucosaImmunopathologymedicineAnimalsHumansEsophagusChildFluorescent Antibody Technique IndirectAutoantibodiesbiologybusiness.industryGastroenterologyInfantHaplorhinimedicine.diseaseImmunoglobulin ACeliac Diseasemedicine.anatomical_structureGastrointestinal diseaseChild Preschoolbiology.proteinFemaleReagent Kits DiagnosticAntibodybusiness
researchProduct

Citrus limon-derived nanovesicles inhibit cancer cell proliferation and suppress CML xenograft growth by inducing TRAIL-mediated cell death

2015

// Stefania Raimondo 1 , Flores Naselli 1 , Simona Fontana 1 , Francesca Monteleone 1 , Alessia Lo Dico 1 , Laura Saieva 1 , Giovanni Zito 2 , Anna Flugy 1 , Mauro Manno 3 , Maria Antonietta Di Bella 1 , Giacomo De Leo 1 , Riccardo Alessandro 1 1 Dipartimento di Biopatologia e Biotecnologie Mediche, Universita degli Studi di Palermo, sezione di Biologia e Genetica, Palermo, Italy 2 Laboratorio di Ingegneria Tissutale – Piattaforme Innovative per l’Ingegneria Tissutale (PON01–00829), Istituto Ortopedico Rizzoli, Palermo, Italy 3 Istituto di Biofisica, Consiglio Nazionale delle Ricerche, Palermo, Italy Correspondence to: Riccardo Alessandro, e-mail: riccardo.alessandro@unipa.it Keywords: canc…

MaleProteomicsCitrusCell signalingProgrammed cell deathTime Factorsexosome-like nanovesiclesCell SurvivalCellApoptosisMice SCIDBiologyExosomesTNF-Related Apoptosis-Inducing LigandCitrus limon L.; TRAIL-mediated cell death; cancer; exosome-like nanovesiclesCitrus limon L.Mice Inbred NODCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositiveHuman Umbilical Vein Endothelial CellsmedicinecancerAnimalsHumansCell ProliferationPlant ProteinsPlants MedicinalPlant ExtractsCell growthCancermedicine.diseaseTRAIL-mediated cell deathAntineoplastic Agents PhytogenicXenograft Model Antitumor AssaysMicrovesiclesTumor BurdenFruit and Vegetable Juicesmedicine.anatomical_structureOncologyApoptosisImmunologyCancer researchNanoparticlesSignal transductionResearch PaperPhytotherapySignal Transduction
researchProduct

Infrapopliteal Composite Bypass with Autologous Vein and Second Generation Glutaraldehyde Stabilized Human Umbilical Vein (HUV) for Critical Lower Li…

2007

Objective. To audit a single center consecutive series of infrapopliteal composite bypasses with second generation glutaraldehyde stabilized human umbilical vein. Design. Retrospective study. Patients. From January 1996 to July 2006 89 femoro-distal bypasses were constructed in 85 patients with HUV and residual vein segments as composite grafts in the absence of sufficient length of autologous vein. Methods. All patients with infrainguinal bypass operations were registered prospectively. Bypasses to infrapopliteal arteries performed with HUV-composite grafts were reviewed for graft patency, limb salvage, patient survival and possible biodegeneration of the HUV. Results. Early graft thrombos…

MaleReoperationmedicine.medical_specialtyUmbilical VeinsComorbiditySingle CenterUmbilical veinDuplex scanningBlood vessel prosthesisIschemiaLimb salvageAutologous veinVascular PatencyMedicineHumansVeinVascular PatencyAgedRetrospective StudiesMedicine(all)Aged 80 and overBioprosthesisLegbusiness.industryAnastomosis SurgicalGraft Occlusion VascularRetrospective cohort studyFemoral VeinMiddle AgedSurgeryBlood Vessel Prosthesismedicine.anatomical_structureFemaleSurgerybusinessCardiology and Cardiovascular MedicineHumanJournal of Vascular Surgery
researchProduct